Searchable abstracts of presentations at key conferences in endocrinology

ea0056p138 | Endocrine tumours and neoplasia | ECE2018

Evaluation of neurofibromatosis type 1 and gastroenteropancreatic neuroendocrine tumors.

Percovich Juan Carlos , Atencia Jose , Garcia Rogelio , Sambo Marcel , Blanco Montserrat , Rotger Amanda , Lopez Dolores , Olmedilla Yoko , Picallo Maria , Velez Marian , Agreda Javier , Brox Noemi , Monereo Susana

Introduction: Neurofibromatosis type 1 (NF1) is an autosomal dominant condition with an incidence of 1 in 2600 to 3000 individuals. Patients with this disorder are characterized by multiple neurofibromas, caf-au-lait macules, axillary freckling, optic gliomas, iris hamartomas, and skeletal abnormalities. Overall risk of developing neoplasms is approximately 2 to 4-fold higher in patients with NF1, with a risk of malignancy estimated between 5 and 15%. Endocrinopathies are some...

ea0049ep1030 | Pituitary - Clinical | ECE2017

Hormone and tumor responses to primary or pre-operative therapy with somatostatin analogs in acromegaly and the relation with T2-weighted MRI signal

Picallo Maria , Centeno Rogelio Garcia , Guerra Aurelio Lopez , Olmedilla Yoko Lucia , Arnoriaga Maria , Requena Maria , Agreda Javier , Andia Victor , Sambo Marcel , Monereo Susana , Velez Maria Angeles , Weber Bettina , Atencia Jose

Objective: Study of the efficacy of SSA in the biochemical and tumour control and the relation between the T2-weighted MRI signal intensity and the response to SSA.Material and methods: 16 patients with GH-secreting pituitary adenomas (7♂/9♀) that received primary or pre-operative treatment with SSA. We classified them according to baseline T2-weighted MRI sequences as Hypo-intense (Ha) and No-Hypo-intense adenomas (no-Ha). Results expressed ...